We have worked closely with Gulf Biotech to develop a brand that reflects the company’s ambitions to be a regional leader in biotechnology and research.
Currently, 296 million vials of insulin are consumed annually, yet demand still outweighs supply in the Gulf region.
In light of such demand, Gulf Biotechnology Company investment has been spearheaded by Bahrain and Saudi Arabia. GBC will be a multipurpose manufacturing plant for the fill & finish of Active Biological Substance (ABS) including human insulin in the Kingdom of Bahrain.
This multimillion investment needed a strong brand identity that would elevate its presence internationally, appeal to the general public and attract new investors.
Gulf Biotechnology Co. had to stand level with a number of well established international brands. The Gulf Biotechnology brand had to reflect a clear, distinct, and highly trustworthy identity which reflects the company’s technological development and high-end products.
The assignment required an understanding of the pharmaceutical industry, Gulf Biotechnology Co as an organisation, its positioning amidst high end investors, and other pharmaceutical organisations.
After in-depth research into the key descriptors of Gulf Biotech and analysing the competition landscape, both regionally and globally, we created an identity which is visually unique in the pharmaceutical industry and effectively reflects the company’s values.
Working closely with Gulf Biotech, we developed the concept into a full set of brand assets including guidelines, stationery and marketing collateral.